Erbin在食管鳞状细胞癌中的表达及其与患者预后的关系

王璐瑶; 于佳乐; 刘帅莹; 董彩凤; 白春英; 张俊毅

doi:10.3969/j.issn.1000-8179.2019.12.365

Erbin在食管鳞状细胞癌中的表达及其与患者预后的关系

doi: 10.3969/j.issn.1000-8179.2019.12.365

王璐瑶^{①, ②,},
于佳乐^③,
刘帅莹^③,
董彩凤^④,
白春英^⑤,
张俊毅^③, ,

①.
锦州医科大学赤峰学院研究生培养基地（内蒙古自治区赤峰市024000）
②.
赤峰学院附属医院皮肤科
③.
赤峰学院附属医院病理科
④.
赤峰学院附属医院呼吸内科
⑤.
内蒙古人类遗传病研究重点实验室

基金项目:

国家自然科学基金项目 81860507

国家自然科学基金项目 81860496

内蒙古自然科学基金项目 2018MS08137

详细信息

作者简介:
王璐瑶专业方向为食管癌的诊断研究E-mail：wangluyao@163.com

通讯作者:
张俊毅 zhangjunyi77@sina.com

计量
- 文章访问数: 72
- HTML全文浏览量: 16
- PDF下载量: 29
- 被引次数: 0
出版历程
- 收稿日期: 2019-03-30
- 修回日期: 2019-06-25
- 刊出日期: 2019-06-30

Expression of Erbin in esophageal squamous cell carcinoma and its relationship with patient prognosis

Wang Luyao^{①, ②
,},
Yu Jiale^③,
Liu Shuaiying^③,
Dong Caifeng^④,
Bai Chunying^⑤,
Zhang Junyi^{③
, ,}

①.
Department of Postgraduate Training Base of Chifeng University, Jinzhou Medical University, Chifeng 024000, China
②.
Department of Dermatology, Affiliated Hospital of Chifeng University, Chifeng 024000, China
③.
3 Department of Pathology, Affiliated Hospital of Chifeng University, Chifeng 024000, China
④.
Department of Pneumology, Affiliated Hospital of Chifeng University, Chifeng 024000, China
⑤.
Key Laboratory of Human Genetic Diseases Research in Inner Mongolia, Chifeng University, Chifeng 024000, China

Funds:

the National Natural Science Foundation of China 81860507

the National Natural Science Foundation of China 81860496

the Natural Science Foundation of Inner Mongolia 2018MS08137

More Information

Corresponding author: Lun Zhang; E-mail:zhanglun@tjmuch.com

摘要

摘要: 目的探讨Erbin在食管鳞状细胞癌(esophageal squamous cell carcinoma, ESCC)中的表达意义及其与患者预后的关系。方法利用免疫组织化学法检测含有299例食管癌病例的组织芯片中Erbin的表达情况, 并分析Erbin的表达与临床病理参数和患者生存时间的关系, 采用Cox回归预测各临床病理参数的危险度。此外, 借助蛋白印迹和PCR方法检测25例冷冻的食管癌组织和癌旁正常组织中Erbin的蛋白和基因表达。结果与癌旁正常食管上皮相比, Erbin蛋白和mRNA在ESCC组织中的表达显著增高(55.2%vs.0, P< 0.05), 且Erbin的高表达与患者的TNM分期(64.9%vs.47.3%, P=0.002)和淋巴结转移状态密切相关(65.5%vs. 45.0%, P< 0.001), Erbin的高表达也与患者的不良预后密切相关(P< 0.05)。结论 Erbin在食管鳞状细胞癌中表达增高并与患者的不良预后密切相关, 提示Erbin可能是一个重要的肿瘤患者预后的生物标记物。
- Erbin /
- 食管鳞状细胞癌 /
- 预后
Abstract: Objective To explore the significance of Erbin expression in esophageal squamous cell carcinoma (ESCC) and its relationship with patient prognosis. Methods Erbin expression in a tissue chip containing samples from 299 cases were examined using immunohistochemistry; in addition, the relationship between Erbin expression and clinical-pathological parameters and patient survival time were also analyzed.Cox regression was used to predict the risk of clinical-pathological parameters.The mRNA and protein expression of Erbin was also determined in 25 cases with paired ESCC and normal tissues through polymerase chain reaction (PCR) and Western blot. Results The expression of Erbin protein and mRNA in ESCC were significantly higher than those of normal esophageal epithelium adjacent to cancer (55.2%vs.0, P< 0.05).The high expression of Erbin in ESCC was closely related to TNM stage (64.9%vs.47.3%, P=0.002) and lymph node metastasis (65.5%vs.45.0%, P< 0.001).Moreover, the high expression of Erbin in ESCC was closely related to poor prognosis (P< 0.05). Conclusions Erbin expression was increased in ESCC and was closely related to poor patient prognosis, which suggested that Erbin may be an important biomarker for the prognosis of cancer patients.
- Erbin /
- esophageal squamous cell carcinoma /
- prognosis

HTML全文

图 1 Erbin在正常食管上皮和食管癌组织中的表达

A：Erbin在正常食管上皮的表达；B：Erbin在食管癌组织中的弱阳性表达（+）；C：Erbin在食管癌组织中的中等阳性表达（++）；D：Erbin在食管癌组织中的强阳性表达（+++）。SP法×200

下载: 全尺寸图片幻灯片

图 2 Erbin在正常食管上皮（N）和食管癌组织（T）中的基因（A）和蛋白（B）表达

下载: 全尺寸图片幻灯片

图 3 Erbin在25对正常食管上皮（N）和食管癌组织（T）中的蛋白表达

下载: 全尺寸图片幻灯片

图 4 Erbin在25对正常食管上皮（N）和食管癌组织（T）中的基因表达

下载: 全尺寸图片幻灯片

图 5 ẟ-catenin在正常食管上皮和食管癌组织中的表达

A：ẟ-catenin在正常食管上皮的表达；B：ẟ-catenin在食管癌组织中的弱阳性表达（+）；C：ẟ-catenin在食管癌组织中的中等阳性表达（++）；D：ẟ- catenin在食管癌组织中的强阳性表达（+++）。SP法×100

下载: 全尺寸图片幻灯片

图 6 299例ESCC患者根据Erbin表达状态分类的Kaplan-Meier生存分析

下载: 全尺寸图片幻灯片

表 1 Erbin与δ-catenin在ESCC中表达的相关性

表 2 ESCC中Erbin的表达与各临床病理参数之间的关系

表 3 ESCC中Erbin的表达与各临床病理参数之间的关系

参考文献(16)

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
[2]	Chen W, Zheng R, Baade PD, et al. Cancer Statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. doi: 10.3322/caac.21338
[3]	Liang C, Tao Y, Shen C, et al. Erbin is required for myelination in regenerated axons after injury[J]. J Neurosci, 2012, 32(43):15169-15180. doi: 10.1523/JNEUROSCI.2466-12.2012
[4]	Arikkath J, Israely I, Tao Y, et al. Erbin controls dendritic morphogenesis by regulating localization of ẟ-catenin[J]. J Neurosci, 2008, 28(28):7047- 7056. doi: 10.1523/JNEUROSCI.0451-08.2008
[5]	Jaulin-Bastard F, Arsanto JP, Le Bivic A, et al. Interaction between Erbin and a Catenin-related protein in epithelial cells[J]. J Biol Chem, 2002, 277(4):2869-2875. doi: 10.1074/jbc.M109652200
[6]	Laura RP, Witt AS, Held HA, et al. The Erbin PDZ domain binds with high affinity and specificity to the carboxyl termini of delta-catenin and ARVCF[J]. J Biol Chem, 2002, 277(15):12906-12914. doi: 10.1074/jbc.M200818200
[7]	Wu H, Yao Su, Zhang Shen, et al. Elevated expression of Erbin destabilizes ERα protein and promotes tumorigenesis in hepatocellular carcinoma[J]. J Hepatol, 2017, 66(6):1193-1204. doi: 10.1016/j.jhep.2017.01.030
[8]	Tao Y, Shen C, Luo S, et al. Role of Erbin in ErbB2-dependent breast tumor growth[J]. PNAS, 2014, 111(42):E4429-E4438. doi: 10.1073/pnas.1407139111
[9]	Huang H, Song Y, Wu Y, et al. Erbin loss promotes cancer cell proliferation through feedback activation of Akt- Skp2- p27 signaling[J]. BBRC, 2015, 463(3):370-376. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=b6e3a5e0a0767e2d5ae550f96b8f8be1
[10]	Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual[M]. 8th edition. New York, Springer, 2017:185-202.
[11]	Zhang JY, Bai CY, Bai YQ, et al. The expression of ẟ-catenin in esophageal squamous cell carcinoma and its correlations with prognosis of patients[J]. Hum Pathol, 2014, 45(10):2014-2022. doi: 10.1016/j.humpath.2014.05.014
[12]	Liu D, Shi M, Duan C, et al. Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance[J]. Molecular Immunology, 2013, 56(1-2):104- 112. doi: 10.1016/j.molimm.2013.04.007
[13]	Lebeau S, Masouyé I, Berti M, et al. Comparative analysis of the expression of ERBIN and Erb-B2 in normal human skin and cutaneous carcinomas[J]. Br J Dermatol, 2005, 152(6):1248-1255. doi: 10.1111/j.1365-2133.2005.06687.x
[14]	Yao S, Zheng P, Wu H, et al. Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c- Cbl-mediated ubiquitination and down- regulation of EGFR[J]. J Pathol, 2015, 236(1):65-77. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=994a05d6e4f4363df3dde5d2f4124a03
[15]	Stevens PD, Wen YA, Xiong X, et al. Erbin suppresses KSR1-mediated RAS/RAF signaling and tumorigenesis in colorectal cancer[J]. Cancer Res, 2018, 78(17):4839-4852. doi: 10.1158/0008-5472.CAN-17-3629
[16]	Zhang JY, Wang Y, Zhang D, et al. ẟ-catenin promotes malignant phenotype of non-small cell lung cancer by non-competitive binding to Ecadherin with p120ctn in cytoplasm[J]. J Pathol, 2010, 222(1):76-88.